Testing disagreements hamper Ebola vax search; Admedus begins PhII trial of herpes jab;

> As the Ebola outbreak wanes, disagreements over the most effective testing methods may mean potential vaccines aren't thoroughly vetted. Story

> Admedus Limited will begin a Phase II study of its herpes vaccine this month. More

> Research Triangle Park, NC-based Argos Therapeutics ($ARGS) struck a deal with China-based Lummy Hong Kong to develop cancer immunotherapies in China. Report

> Daiichi Sankyo and Terumo announced their application for manufacturing and sales approval of an intradermal seasonal influenza vaccine in Japan. Release

> GeoVax will seek a dual pathway for advancing its HIV vaccine into human trials. Release

> Scientists believe a new HIV treatment pioneered using an antibody to attack the virus could lead to a vaccine to prevent the infection. Story

And Finally... Los Angeles artist Mary Beth Heffernan delivered a way for Ebola patients to see the faces of those helping. Story

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.

Participation in clinical trials among Black people is low, FDA statistics show, even as drugmakers prioritize including them in COVID-19 shot trials.